



**Adele Cirone Oliva** has decades of finance and healthcare experience, including 20 years in private equity focused on commercial stage specialty pharmaceutical, medical technology, and healthcare service investments. Adele co-founded 1315 Capital in 2014 to establish a firm focused on healthcare growth investing. She was recruited to Quaker Partners in 2007 to expand their growth stage investing practice. Prior to Quaker, Adele was Co-Head of US Healthcare at Apax Partners, where she started in 1997.

Forbes recognized Adele on its Midas List of top 100 technology investors worldwide, top 10 life science investors, and top women in venture capital. In 2016, Adele was recognized by the Philadelphia Business Journal as part of the Power 76 list of the region's most influential people. Prior to entering private equity as a Kauffman Fellow, Adele held roles at CoreStates and Baxter Healthcare. Adele received a BSc from St. Joseph's University and an MBA from Cornell University, where she was awarded the Albert Fried Fellowship.

Adele has served on the board of Ascent Healthcare Solutions (acquired by Stryker), EKR Therapeutics (acquired by Cornerstone Therapeutics), ESP Pharma (acquired by Protein Design Labs), Esprit Pharma (acquired by Allergan), Precision Dermatology (acquired by Valeant), Prometheus Labs (acquired by Nestle), and SkinMedica (acquired by Allergan). She currently serves on the boards of Colorescience, Encore Dermatology, Genoptix, Innovative Health, NovaSom, Onkos Surgical, and TELA Bio.